NovoCure Limited Stock 12‑Month Price Target Cut to $21.33, Implies 62% Upside
NovoCure Limited's average stock price target was reduced by analysts from $25.71 to $21.33, with a range of $15 to $29. This implies a 62% upside from the Oct. 30 closing price. The consensus rating remains 'Buy' among 6 analysts, with 3 Buys and 3 Holds.
How this was made

The 30-second read
Why it matters
Analyst target revisions are a secondary catalyst; they rarely move the stock dramatically unless accompanied by new fundamentals.
Market read
Minor relevance; price‑target cut may cause modest short‑term price adjustment.
What to watch
Potential upcoming trial data or partnership news could offset the target reduction.
Background
The article aggregates analyst consensus price targets without new company disclosures.
Ticker impact
Analysts cut NovoCure's average price target to $21.33, down from $25.71, implying 62% upside from the Oct. 30 close.
potential downward pressure as the market prices in the lower target
A 17% target cut is a material analyst downgrade that typically triggers sell‑side activity.
Market effects
May slightly dampen sentiment in the oncology biotech sector.
Limited to U.S. biotech investors.
Low global impact.
Counterpoint
Some investors may view the 62% upside as a buying opportunity despite the target cut.
Key entities
- companyNovoCure Limited
Biotech firm developing cancer immunotherapy.

